Abstract
Zolpidem is among the most frequently prescribed hypnotic drugs for those who suffer from insomnia. Recent media reports drew attention to driving impairment after zolpidem misuse. This review summarizes the available data on the effects of recommended use and misuse of zolpidem on driving ability and traffic safety. Both experimental studies and roadside evidence were taken into account. From these studies it must be concluded that patients should fully comply with the prescription instructions of zolpidem, i.e. to take the medication just prior to a full 8 hours of uninterrupted sleep. If this strategy is adopted, zolpidem is a safe alternative to benzodiazpine hypnotics and zopiclone who do show significant driving impairment the morning following bedtime administration. However, to ensure traffic safety higher dosages than recommended (10 mg) or allowing less than 8 hours between zolpidem intake and actual operation of a motor vehicle should be avoided.
Keywords: Zolpidem, driving, accidents, compliance
Current Drug Safety
Title: Zolpidem and Traffic Safety - The Importance of Treatment Compliance
Volume: 2 Issue: 3
Author(s): Joris C. Verster, Edmund R. Volkerts, Berend Olivier, William Johnson and Laura Liddicoat
Affiliation:
Keywords: Zolpidem, driving, accidents, compliance
Abstract: Zolpidem is among the most frequently prescribed hypnotic drugs for those who suffer from insomnia. Recent media reports drew attention to driving impairment after zolpidem misuse. This review summarizes the available data on the effects of recommended use and misuse of zolpidem on driving ability and traffic safety. Both experimental studies and roadside evidence were taken into account. From these studies it must be concluded that patients should fully comply with the prescription instructions of zolpidem, i.e. to take the medication just prior to a full 8 hours of uninterrupted sleep. If this strategy is adopted, zolpidem is a safe alternative to benzodiazpine hypnotics and zopiclone who do show significant driving impairment the morning following bedtime administration. However, to ensure traffic safety higher dosages than recommended (10 mg) or allowing less than 8 hours between zolpidem intake and actual operation of a motor vehicle should be avoided.
Export Options
About this article
Cite this article as:
Verster C. Joris, Volkerts R. Edmund, Olivier Berend, Johnson William and Liddicoat Laura, Zolpidem and Traffic Safety - The Importance of Treatment Compliance, Current Drug Safety 2007; 2 (3) . https://dx.doi.org/10.2174/157488607781668882
DOI https://dx.doi.org/10.2174/157488607781668882 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bilayer Tablet Based Chronotherapeutics in the Management of Nocturnal Asthma: An Overview
Recent Patents on Drug Delivery & Formulation Levocetirizine: An Update
Current Medicinal Chemistry Ursolic Acid and Oleanolic Acid: Pentacyclic Terpenoids with Promising Anti-Inflammatory Activities
Recent Patents on Inflammation & Allergy Drug Discovery Probiotics in Curing Allergic and Inflammatory Conditions - Research Progress and Futuristic Vision
Recent Patents on Inflammation & Allergy Drug Discovery The 2010 Patent Landscape for Spleen Tyrosine Kinase Inhibitors+
Recent Patents on Inflammation & Allergy Drug Discovery Past, Present and Future of Nutrigenomics and its Influence on Drug Development
Current Drug Discovery Technologies Paracetamol-Induced Fixed Drug Eruption at an Unusual Site
Recent Patents on Inflammation & Allergy Drug Discovery Potential Genetic Therapies for Acute Lung Injury
Current Gene Therapy The Links Between Sleep Apnea and Chronic Kidney Disease
Current Respiratory Medicine Reviews The Use of <i>Cannabis</i> and Cannabinoid-based Products by Pregnant Women: A Patent Review
Recent Patents on Biotechnology Metabolism of the Endocannabinoids Anandamide and 2-Arachidonoyl Glycerol, A Review, with Emphasis on the Pharmacology of Fatty Acid Amide Hydrolase, A Possible Target for the Treatment of Neurodegenerative Diseases and Pain
Current Medicinal Chemistry - Central Nervous System Agents Hypersensitivity Pneumonitis
Current Pediatric Reviews Anti-Cancer Effects of a New Docosahexaenoic Acid Monoacylglyceride in Lung Adenocarcinoma
Recent Patents on Anti-Cancer Drug Discovery Platelet Function in Inflammatory Diseases: Insights from Clinical Studies
Inflammation & Allergy - Drug Targets (Discontinued) Recent Updates on the Systemic and Local Safety of Intranasal Steroids
Current Drug Metabolism Expression and Function of Anti-Inflammatory Interleukins: The Other Side of the Vascular Response to Injury
Current Vascular Pharmacology B-Cell Based Gene Therapy for Autoimmune Diseases
Infectious Disorders - Drug Targets Alpha-1 Antitrypsin Deficiency and Chronic Obstructive Pulmonary Disease: Between Overlaps, Phenotypes and Illnesses
Current Respiratory Medicine Reviews The Mast Cell: A Potential Therapeutic Target in Myocardial Infarction
Drug Design Reviews - Online (Discontinued) Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry